Insulet Corporation · NASDAQ:PODD
Insulet — Investor Presentation (May 2024)
21 slides from Insulet's investor presentation, May 2024
Slide 1: Insulet Corporation Investor Presentation May 2024
Insulet Corporation Investor Presentation Kimsue May 2024 Podder since 2023
Slide 2: Driving Continued Growth and Success
Driving Continued Growth and Success 1 Achieving our mission with robust innovation and commercial pipeline 2 Continued strong execution driving financial results 3 Capitalizing on massive opportunities in type 2 diabetes and international markets Eloise Podder 4 since Unlocking Omnipod 5 potential
Slide 3: Forward Looking Statement; Non-GAAP Financial Measures
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 4: Achieving Our Mission with Market-Leading Innovation
Achieving Our Mission with Market-Leading Innovation Our Mission: Simplify Life for People with Diabetes Market-Leading Technology Omnipod Reduce Improve platform burden outcomes Market-Leading Revenue Growth Competitive Advantages Long-Term Skilled talent with deep in-house expertise Value Creation
Slide 5: Strong Fundamentals Powering Financial Results
Strong Fundamentals Powering Financial Results Revenue Adj. Gross Profit & Margin1 Adj. Operating Income & Margin2 $’s in Billions $’s in Billions $’s in Millions $1.8 $1.7 $1.2 67.7% $240 23% CAGR +260 bps +550 bps 12.3% $1.6 $1.0 $200 $1.4 $1.3 66.2% $1.2 $1.1 $0.8 68.4% $160 $0.9 11.5% 9.5% $1.0
Slide 6: Delivering Results while Expanding Our Portfolio
Delivering Results while Expanding Our Portfolio 2023 ~425,0002 Q1 2024 Q1 2024 Total Estimated Active Global 8th Customer Base 23%3 460 bps3,4 Consecutive year of U.S. Revenue Gross margin expansion 20% or more ~250,0002 21%1,3 740 bps3,4 Total Company Revenue growth1 Using Omnipod 5 Total Omnipod
Slide 7: Well Positioned for the Massive Market Opportunity
Well Positioned for the Massive Market Opportunity ~64M ~11M +3M Requiring Insulin Total Addressable U.S. Basal Opportunity Worldwide1 Market2 (Future TAM opportunity) Market Market Size Type 1 45% Insulin Intensive Type 2 55% 1. Source: IDF Atlas 10th Edition. 7 2. Comprised of ~1.5M type 1 and ~2.
Slide 8: Omnipod 5 Delivers Exciting Clinical Outcomes
Omnipod 5 Delivers Exciting Clinical Outcomes Time below Age Group Time in range Time in closed loop range (<70) 14-70 yrs1 73.9% 1.1% 96.7% 6-13 yrs1 68.0% 1.5% 96.4% Pod shown without necessary adhesive. Omnipod 5 shown without sensor. 2-5 yrs2 68.1% 1.9% 97.8% Strong performance in the pivotal tr
Slide 9: Proven Real-World Results in 70,000 Omnipod 5 Users
Proven Real-World Results in 70,000 Omnipod 5 Users1 Time below Age Group Time in range Time in closed loop2 range (<70) 2 Adults 69% 1.0% 94% (18+ yrs) Pediatrics 64% 1.4% 95% Pod shown without necessary adhesive. Omnipod 5 shown without sensor. (2-17 yrs) • 71% time in range for prior MDI users2 •
Slide 10: Winning on All Dimensions with Omnipod 5
Winning on All Dimensions with Omnipod 5 The Omnipod Platform + Omnipod 5 with AID = Obvious • No needles or tubes • Cutting-edge algorithm using micro-dose technology Choice • Discreet, wearable, disposable • Industry-leading time in range • Pay-as-you-go economics for customers and payors • Very f
Slide 11: Omnipod 5 Simplifies Diabetes Management
Omnipod 5 Simplifies Diabetes Management Outcomes enabled by simplicity World-Class Data & Driving Outcomes Automated insulin User Experience Connectivity delivery Tubeless, phone-controlled, Always cloud simple interface connected Pipeline Advanced Performance with Simplicity Advanced Outcomes with
Slide 12: Building a Full Range of Type 2 Diabetes Options
Building a Full Range of Type 2 Diabetes Options – Omnipod is the Clear Choice Patient AID Journey New Market Omnipod GO to deliver daily basal insulin Feature Set As insulin needs progress, … or Omnipod 5 customers move downstream to either to better manage disease Basal Rate Only Omnipod DASH ...
Slide 13: Innovation Drives Horizons of Growth
Innovation Drives Horizons of Growth • Expand the Omnipod 5 platform • Continue U.S. growth Drive Omnipod • Additional launches in existing international markets 5 Growth • Expand CGM compatibility • iOS phone control • Innovate and expand product indications and global presence • Omnipod GO and Omn
Slide 14: Insulet Sustainability
Insulet Sustainability DELIVER GROWTH WITH PURPOSE: INNOVATING TO IMPROVE LIVES AND PRESERVE OUR PLANET Sustainability Strategic Pillars FY 2023 Accomplishments1 Resilient Operations • Increased renewable energy generation potential by 802kW via the completion of a second solar installation at our A
Slide 15: Driving Continued Growth and Success
Driving Continued Growth and Success 1 Achieving our mission with robust innovation and commercial pipeline 2 Continued strong execution driving financial results 3 Capitalizing on massive opportunities in type 2 diabetes and international markets Holly Podder 4 since Unlocking Omnipod 5 potential i
Slide 16: Thank You
Thank Thank You You
Slide 17: Appendix
Appendix Insulet
Slide 18: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures Quarter Ended March 31, 2024 2023 Percent Change Currency Impact Constant Currency U.S. Omnipod $317.7 $259.0 22.7% -% 22.7% International Omnipod 115.3 98.6 16.9% 2.1% 14.8% Total Omnipod 433.0 357.6 21.1% 0.6% 20.5% Drug Delivery 8.7 0.5 1,640.0% -% 1,640.0% Tot
Slide 19: Reconciliation of Non-GAAP Measures (continued)
Reconciliation of Non-GAAP Measures (continued) Year Ended December 31, 2023 (dollars in millions) Gross Profit Gross Margin Operating Income Operating Margin GAAP $1,159.9 68.3% $220.0 13.0% Voluntary medical device corrections1 (11.5) (11.5) Non-GAAP $1,148.4 67.7% $208.5 12.3% 19 1. Represents to
Slide 20: Reconciliation of Non-GAAP Measures (continued)
Reconciliation of Non-GAAP Measures (continued) Year Ended December 31, 2022 (dollars in millions) Gross Profit Gross Margin Operating Income Operating Margin GAAP $805.6 61.7% $37.6 2.9% Voluntary medical device corrections1 57.9 57.9 Legal costs2 - 25.2 CEO transition costs3 - 3.4 Non-GAAP $863.5
Slide 21: Reconciliation of Non-GAAP Measures (continued)
Reconciliation of Non-GAAP Measures (continued) Year Ended December 31, 2020 (dollars in millions) Operating Income Operating Margin GAAP $51.5 5.7% Cumulative amortization expense1 14.6 Non-GAAP $66.1 7.3% 21 1. Represents cumulative amortization expense related to the resolution of a purchase pric